Skip to main content
The Journal

Inside the Nasty Fight to Take Over Hollywood

16 min episode · 2 min read
·

Episode

16 min

Read time

2 min

Topics

Relationships, Fundraising & VC, Leadership

AI-Generated Summary

Key Takeaways

  • Content library as competitive moat: Legacy TV franchises with hundreds of episodes — Friends, Harry Potter, DC properties — are the primary acquisition target because they reduce streaming churn. Platforms acquiring deep catalogs retain subscribers longer than those relying solely on original programming.
  • Political lobbying as M&A strategy: Paramount deployed Washington connections aggressively, with CEO David Ellison attending Trump events and legal officers lobbying Republican officials against Netflix's bid. Companies without DC relationships — like Netflix, which struggled at Senate hearings — face structural disadvantage in major media mergers.
  • Debt load as execution risk: The merged Paramount-Warner entity carries $79 billion in debt while committing to 30 theatrical films annually. Industry observers question whether that production volume is financially sustainable alongside cable network operations and mandatory debt servicing.
  • Media consolidation shifts creative leverage: When two major studio groups merge into one entity controlling CBS, CNN, HBO, Paramount Pictures, and Warner Bros., writers, producers, and below-the-line workers lose negotiating leverage. Fewer competing buyers means reduced ability to shop projects or negotiate favorable terms.

What It Covers

Paramount Skydance outbids Netflix in a nine-round acquisition battle for Warner Brothers Discovery, ultimately offering $81 billion — including a $3 billion Netflix breakup fee — to create a debt-heavy media conglomerate controlled by the Ellison family.

Key Questions Answered

  • Content library as competitive moat: Legacy TV franchises with hundreds of episodes — Friends, Harry Potter, DC properties — are the primary acquisition target because they reduce streaming churn. Platforms acquiring deep catalogs retain subscribers longer than those relying solely on original programming.
  • Political lobbying as M&A strategy: Paramount deployed Washington connections aggressively, with CEO David Ellison attending Trump events and legal officers lobbying Republican officials against Netflix's bid. Companies without DC relationships — like Netflix, which struggled at Senate hearings — face structural disadvantage in major media mergers.
  • Debt load as execution risk: The merged Paramount-Warner entity carries $79 billion in debt while committing to 30 theatrical films annually. Industry observers question whether that production volume is financially sustainable alongside cable network operations and mandatory debt servicing.
  • Media consolidation shifts creative leverage: When two major studio groups merge into one entity controlling CBS, CNN, HBO, Paramount Pictures, and Warner Bros., writers, producers, and below-the-line workers lose negotiating leverage. Fewer competing buyers means reduced ability to shop projects or negotiate favorable terms.

Notable Moment

Netflix's stock rose sharply the moment markets confirmed the company had exited the bidding — signaling investors viewed the $72 billion Warner acquisition as a financial risk rather than a strategic necessity, contradicting the narrative that Netflix needed the deal.

Know someone who'd find this useful?

Episode Transcript

One of the biggest dramas in Hollywood in the past year has been the fight over Warner Brothers' Discovery. Warner Brothers Discovery announced today that it is putting itself up for sale. Paramount made three bids to buy the company over the past couple of weeks here. It first, offered $19, then raised that to $22, the latest. Warner Brothers Discovery has entered exclusive negotiations to sell its film and TV studios and HBO Max streaming service to Netflix. In December, Warner announced that it had accepted Netflix's offer of $72,000,000,000. The Warner Brothers bidding saga seemed to finally come to an end. Only, Paramount still refused to take no for an answer. Tonight, a plot twist in a Hollywood blockbuster deal. Paramount Skydance is challenging Netflix with their own offer to purchase. Our colleague, Joe Flint, has been following the whole story. Netflix had a deal with Warner, but Paramount refused to throw in the towel. And they kept coming back with more offers. And even though none of these offers they were making were really moving the needle for Warner, they were making offers. They were lobbying lawmakers to argue against Netflix. That offer was the ninth one from Paramount Skydance's CEO, David Ellison. What does this tell you about how important this deal was to Paramount? This deal is almost, one could say, was a make or break for the whole Ellison strategy. And they felt that Paramount on its own didn't have the size and scale to compete with a Netflix, a Disney, all these other bigger players in the streaming wars. But if they could get Warner as well, and the Warner library, and HBO Max, and the cable networks, Paramount felt they really needed Warner to have a strong hand to go up against a Disney and a Netflix. So they really did need to have this. Welcome to The Journal, our show about money, business, and power. I'm Jessica Mendoza. It's Thursday, March 5. Coming up on the show, how Paramount managed to snatch a last minute victory in the fight for Warner Brothers. This episode of The Journal is presented by Intuit Enterprise Suite. If your finance team spends more time finding data than using it, if there's one entity here and one here and one here and one here, if scaling your business feels like starting over, you need the Intuit ERP. Intuit Enterprise Suite, the AI native ERP is here from the makers of QuickBooks. Learn more at intuit.com/erp. For adults with Crohn's disease or ulcerative colitis symptoms, every choice matters. Tremfya offers self injection or intravenous infusion from the start. Tremfya is administered as injections under the skin or infusions through a vein every four weeks, followed by injections under the skin every four or eight weeks. If your doctor decides that you can self inject Tremfya, proper training is required. Tremfya is a prescription medicine used to treat adults with moderately to severely active Crohn's disease and adults …

Get the full transcript (2,544 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all The Journal transcripts →

You just read a 3-minute summary of a 13-minute episode.

Get The Journal summarized like this every Monday — plus up to 2 more podcasts, free.

Pick Your Podcasts — Free

Keep Reading

More from The Journal

We summarize every new episode. Want them in your inbox?

Similar Episodes

Related episodes from other podcasts

Explore Related Topics

This podcast is featured in Best News Podcasts (2026) — ranked and reviewed with AI summaries.

You're clearly into The Journal.

Every Monday, we deliver AI summaries of the latest episodes from The Journal and 192+ other podcasts. Free for one show.

Start My Monday Digest

No credit card · Unsubscribe anytime